Our pipeline spans multiple therapeutic programs across precision oncology and targeted therapeutics. We focus on biologically validated disease pathways, including oncogenic signaling, tumor microenvironment biology, synthetic chemistry, and next-generation targeted delivery approaches.   

At Tyligand, we believe differentiated science is the foundation of meaningful clinical impact. Our goal is to build a globally competitive biotechnology company capable of delivering innovative medicines to patients worldwide through scientific excellence, operational focus, and long-term commitment to patients.

Our mission is to harness science and technology to safeguard the dignity of life. We focus on discovering and developing differentiated, innovative, and accessible medicines that address significant unmet medical needs for patients worldwide.

We are committed to translating scientific insight into therapies with the potential to improve clinical outcomes, enhance quality of life, and create lasting value for patients, employees, partners, investors, and society.

Integrated Innovation Across Small Molecules and ADCs

Tyligand has built fully integrated capabilities spanning target biology, medicinal chemistry, linker-payload design, antibody–drug conjugation, translational research, and drug development. These capabilities allow us to leverage multiple therapeutic modalities and adopt the most effective approach for each disease target.

Our small-molecule platform focuses on designing potent and selective drug candidates against clinically relevant targets, including key signaling pathways involved in tumor growth and disease progression.

Our ADC platform is designed to enable targeted delivery of therapeutic payloads to disease-relevant cells, supporting the development of differentiated candidates with improved therapeutic potential.

Together, these platforms form the foundation of our pipeline strategy and enable us to pursue drug candidates with solid scientific rationale, clear differentiation, and meaningful clinical potential.

People

People are the foundation of our science and our success. We are committed to building a respectful, inclusive, and empowering environment where employees can pursue meaningful scientific challenges, develop their talents, and realize their full potential.

Integrity

Integrity is the foundation of scientific credibility and sustainable innovation. We are committed to rigorous science, data-driven decision-making, transparency, and the highest standards of professional conduct. We believe that lasting commercial success can only be achieved through scientific rigor, ethical responsibility, and respect for patients.

Innovation

Innovation is at the core of who we are. We believe transformative medicines emerge from deep scientific insight, intellectual curiosity, and disciplined execution. We foster an environment where scientists are empowered to challenge assumptions, pursue bold ideas, and translate discovery into meaningful therapies for patients.

Responsibility

We recognize the responsibility that comes with advancing science for human health. We are committed to patients, employees, families, collaborators, investors, and society. As we pursue innovation, we remain guided by accountability, respect, and long-term purpose.

Since our founding, Tyligand has evolved from a discovery platform into a clinical-stage biotechnology company with differentiated therapeutic programs and technology platforms. Our milestones reflect the continuous advancement of our scientific capabilities, pipeline, and translational expertise as we work to bring innovative medicines closer to patients worldwide.